$INAB News

IN8bio Publishes Nature Communications Review Highlighting Engineered γδ T Cell Cancer Therapies And Combination Treatment Advances

IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma

IN8bio Presents New Translational Data Of Its DeltEx DRI Platform At ISCT 2026 Annual Meeting And ASGCT 2026 Annual Meeting

IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

IN8bio Q1 EPS $(0.26) Beats $(0.69) Estimate

IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

HC Wainwright & Co. Reiterates Buy on IN8bio, Maintains $6 Price Target

IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026

IN8bio Q4 EPS $(0.26) Beats $(0.51) Estimate

IN8bio Q4 EPS $(0.26) Beats $(0.51) Estimate

IN8bio to Present at TD Cowen 46th Annual Health Care Conference

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer

IN8bio Promotes Kate Rochlin To President, COO, Effective Immediately

IN8bio to Present at Upcoming Investor and Scientific Conferences in February

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

IN8bio Reports Updated Clinical Data From INB-200 Phase 1 And INB-400 Phase 2 Trials In Newly Diagnosed Glioblastoma

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

IN8bio Prices Private Placement For Gross Proceeds Up To $40.2M To Advance Novel Gamma-Delta T Cell Engager

Shares of IN8bio are trading higher. The company announced consolidated data from its Phase 1 single-center clinical trial of INB-200 and Phase 2 multi-center trial of INB-400 for the treatment of patients with newly diagnosed glioblastoma at 2025 SNO Annual Meeting.